Plaintiff

Ascendis Pharma A/S

3 cases as plaintiff.

Cases: 3
Active: 0; 3 closed
Filed: 2025
Top venue: N.D. California; 2 cases

Also appears as a defendant in 1 case → View as defendant

Watchlist

Get alerted when Ascendis Pharma A/S sues again.

Email-only, free, anonymous. We'll notify you when Ascendis Pharma A/S files another patent-infringement lawsuit. One-click unsubscribe from any alert.

Ascendis Pharma A/S v. BioMarin Pharmaceutical Inc.

stayed; resolved by settlement

Docket:: 4:25-cv-05696
Court:: United States District Court for the Northern District of California
Filed:: 2025-07-07
Terminated:: 2026-08-30

Patents:RE48267 8198242 8906847

π Ascendis Pharma A/S Δ BioMarin Pharmaceutical Inc.

Ascendis Pharma A/S filed a declaratory judgment action against BioMarin; the docket listed U.S. Patents 8,198,242, 8,906,847, and RE48,267. The district court granted BioMarin's motion for a discretionary stay on September 19, 2025, and denied Ascendis's mandatory stay motion as moot; the case was later resolved by the August 2026 global settlement.

Ascendis Pharma A/S et al. v. BioMarin Pharmaceutical Inc.

voluntarily dismissed

Docket:: 4:25-cv-03302
Court:: United States District Court for the Northern District of California
Filed:: 2025-04-11
Terminated:: 2025-07-07

Patents:RE48267

π Ascendis Pharma A/S π Ascendis Pharma Growth Disorders A/S π Ascendis Pharma, Inc.Δ BioMarin Pharmaceutical Inc.

Ascendis entities filed a declaratory judgment action of non-infringement against BioMarin, also invoking the 35 U.S.C. § 271(e)(1) safe harbor. Ascendis voluntarily dismissed without prejudice on July 7, 2025, stating it would refile to seek a mandatory stay under 28 U.S.C. § 1659(a)(2).

Ascendis Pharma A/S v. BioMarin Pharmaceutical Inc.

settled

Docket:: 4:25-cv-05696
Court:: U.S. District Court for the Northern District of California
Terminated:: 2026-08-30

Patents:8377884

π Ascendis Pharma A/S Δ BioMarin Pharmaceutical Inc.

Declaratory-judgment/safe-harbor action by Ascendis Pharma A/S against BioMarin involving §271(e)(1) and a forum dispute with the parallel ITC action. US 8,377,884 was cited in BioMarin's filings as Exhibit 32 in connection with Ascendis's ITC prior-art/protest arguments concerning RE'267, not as an asserted patent. Resolved by the August 30, 2026 global settlement.